Millions of French allergy sufferers could face a critical shortage of a key medication this spring, as manufacturing delays threaten to halt supplies of Kenacort Retard® 40mg/1ml by May 2026. The injectable corticosteroid, widely used to treat severe allergic reactions, dermatological conditions, and inflammatory diseases, is already subject to rationing as of February 2026, according to the French National Agency for the Safety of Medicines and Health Products (ANSM).
The looming shortage stems from a “production delay” at manufacturer Bristol-Myers Squibb, the ANSM announced to healthcare professionals on February 17, 2026. To mitigate a complete stockout, the company has implemented a quantitative rationing system, limiting the amount of the drug distributed to pharmacies nationwide. This measure aims to equitably distribute available doses over the next three months, aligning with national market needs.
What is Kenacort Retard® and Why is it Important?
Kenacort Retard® is a potent anti-inflammatory medication used when other allergy treatments have failed. Its extended-release formulation allows for a prolonged effect, sometimes lasting several weeks after a single injection. The drug is prescribed for a range of conditions, including seasonal allergic rhinitis, severe skin ailments, and certain rheumatic diseases like inflammatory arthritis and osteoarthritis flares. The “Retard” designation signifies its gradual-release properties, distinguishing it from other, shorter-acting corticosteroids.
The potential disruption in supply comes at a particularly sensitive time, as warmer weather approaches and pollen counts begin to rise, exacerbating allergy symptoms for millions. Approximately 30% of French citizens suffer from seasonal allergies, experiencing symptoms like a runny nose, itchy eyes, and fatigue. For many, Kenacort Retard® has become an essential part of managing these debilitating conditions.
What Alternatives are Available?
Bristol-Myers Squibb acknowledges the potential for a complete stockout of Kenacort Retard® in city pharmacies by May 2026, and at hospitals by late May. However, the company states that alternative injectable corticosteroids are available. These include betamethasone, prednisolone, methylprednisolone, and dexamethasone. All belong to the same class of anti-inflammatory drugs and can effectively reduce inflammation and modulate the immune response.
However, these alternatives are not identical to Kenacort Retard®. The extended-release formulation of Kenacort Retard® provides a sustained effect not always matched by other corticosteroids, potentially requiring adjustments to dosage or frequency of administration. Patients currently using Kenacort Retard® are advised to consult their physician to discuss potential adjustments to their treatment plan and avoid abrupt interruption of therapy.
Understanding Corticosteroids and Allergic Reactions
Corticosteroids work by suppressing the immune system’s response to allergens, reducing inflammation and alleviating allergy symptoms. They are often prescribed when other treatments, such as antihistamines and nasal sprays, prove insufficient. While effective, corticosteroids can have side effects, and their employ should be carefully monitored by a healthcare professional. The Journal des Femmes provides further information on corticosteroids and their uses.
What Should Patients Do Now?
Patients currently prescribed Kenacort Retard® should not discontinue their medication without consulting their doctor. Healthcare providers are aware of the potential shortage and are prepared to discuss alternative treatment options. The ANSM is closely monitoring the situation and working with Bristol-Myers Squibb to resolve the production issues. Individuals experiencing severe allergic reactions should seek immediate medical attention.
The situation highlights the fragility of pharmaceutical supply chains and the potential impact of manufacturing disruptions on patient care. While alternatives exist, the unique properties of Kenacort Retard® mean that switching medications may require careful consideration and individualized treatment plans.
The next update from Bristol-Myers Squibb regarding the resumption of Kenacort Retard® production is expected in early April 2026. Patients and healthcare professionals are encouraged to monitor the ANSM website for further information, and guidance.
Have you been affected by this medication shortage? Share your experiences and concerns in the comments below.
Disclaimer: This article provides general information and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
